GILEAD SCIENCES SL
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 47
- Registration Number
- NCT02226549
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 269
- Registration Number
- NCT02220998
- Locations
- 🇺🇸
Emory university, Atlanta, Georgia, United States
Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection
Phase 2
Completed
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: LDV/SOFDrug: Placebo
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT02219685
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 88
- Registration Number
- NCT02216409
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT02209987
Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 273
- Registration Number
- NCT02202980
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 558
- Registration Number
- NCT02201953
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 268
- Registration Number
- NCT02201901
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 741
- Registration Number
- NCT02201940
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
Phase 1
Completed
- Conditions
- Hepatitis C Virus Infection
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 101
- Registration Number
- NCT02185794
© Copyright 2025. All Rights Reserved by MedPath